BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 994219)

  • 21. Effect of local injection of Corynebacterium parvum on the growth of a murine fibrosarcoma.
    Woodruff MF; Dunbar N
    Br J Cancer; 1975 Jul; 32(1):34-41. PubMed ID: 1080671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. III. Effect of C. parvum on cyclophosphamide metabolism.
    Fisher B; Wolmark N; Rubin H
    J Natl Cancer Inst; 1976 Jul; 57(1):225-6. PubMed ID: 1003505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice.
    Wolmark N; Fisher B
    Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513
    [No Abstract]   [Full Text] [Related]  

  • 24. The distribution and persistence in vivo of Corynebacterium parvum in relation to its antitumor activity.
    Scott MT; Milas L
    Cancer Res; 1977 Jun; 37(6):1673-9. PubMed ID: 870181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of the incidence of death with spontaneous tumours in DBA/2 mice after Corynebacterium parvum-mediated rejection of syngeneic tumours.
    Likhite VV
    Nature; 1976 Feb; 259(5542):397-9. PubMed ID: 1250378
    [No Abstract]   [Full Text] [Related]  

  • 26. The delayed rejection of tumors formed from the administration of tumor cells mixed with killed Corynebacterium parvum.
    Likhite VV; Halpern BN
    Int J Cancer; 1973 Nov; 12(3):699-704. PubMed ID: 4524799
    [No Abstract]   [Full Text] [Related]  

  • 27. Studies with a spontaneous mouse tumor. I. Growth in normal mice and response to Corynebacterium parvum.
    Woodruff MF; Whitehead VL; Speedy G
    Br J Cancer; 1978 Mar; 37(3):345-55. PubMed ID: 638014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Corynebacterium parvum on tumor growth in normal and athymic (nude) mice.
    Woodruff MF; Warner NL
    J Natl Cancer Inst; 1977 Jan; 58(1):111-6. PubMed ID: 299893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rejection of mammary adenocarcinoma cell tumors and the prevention of progressive growth of incipient metastases following intratumor permeation with killed Bordetella pertussis.
    Likhite VV
    Cancer Res; 1974 Oct; 34(10):2790-4. PubMed ID: 4370327
    [No Abstract]   [Full Text] [Related]  

  • 30. Study of the mechanism of Corynebacterium parvum anti-tumour activity. I. Protective effect on the growth of two syngeneic tumours.
    Mazurek C; Chalvet H; Stiffel CL; Biozzi G
    Int J Cancer; 1976 Apr; 17(4):511-7. PubMed ID: 946965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Further observations on the effect of C. parvum and anti-tumour globulin on syngeneically transplanted mouse tumours.
    Woodruff MF; Inchley MP; Dunbar N
    Br J Cancer; 1972 Apr; 26(2):67-76. PubMed ID: 5038327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antitumoral activity of various doses of corynebacterium parvum as a function of the age of mice].
    Stiffel C; Chalvet H; Mazurek C
    Ann Inst Pasteur Immunol (1985); 1985; 136D(1):19-27. PubMed ID: 3840664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation therapy and Corynebacterium parvum in the treatment of murine tumors.
    Suit HD; Sedlacek RS; Silobrcic V; Linggood RM
    Cancer; 1976 Jun; 37(6):2573-9. PubMed ID: 949676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of purified cell walls from Corynebacterium parvum.
    Riveros-Moreno V; Bomford R; Scott MT
    J Natl Cancer Inst; 1978 Mar; 60(3):653-8. PubMed ID: 625069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C. parvum treatment of transplanted rat tumours of spontaneous origin.
    Willmott N; Pimm MV; Baldwin RW
    Int J Cancer; 1979 Sep; 24(3):323-8. PubMed ID: 385514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suitability of rat mammary adenocarcinoma 13762 as a model for BCG immunotherapy.
    Kreider JW; Bartlett GL; Purnell DM
    J Natl Cancer Inst; 1976 Apr; 56(4):797-802. PubMed ID: 815563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
    Fisher B; Gebhardt M
    Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):861-5. PubMed ID: 4213016
    [No Abstract]   [Full Text] [Related]  

  • 39. Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations.
    Dye ES; North RJ; Mills CD
    J Exp Med; 1981 Sep; 154(3):609-20. PubMed ID: 6974214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma.
    Kreider JW; Bartlett GL; Boyer CM; Purnell DM
    Cancer Res; 1979 Mar; 39(3):987-92. PubMed ID: 427785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.